Actively Recruiting
Evaluating Intravenous Telisotuzumab Adizutecan with FOLFOX Compared to Standard Chemotherapy for Adults with Metastatic Pancreatic Ductal Adenocarcinoma in a Phase 23 Randomized Study
Led by AbbVie · Updated on 2026-10-13
900
Participants Needed
22
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and disease activity changes of telisotuzumab adizutecan combined with fluorouracil, folinic acid, and oxaliplatin FOLFOX in adults with metastatic pancreatic ductal adenocarcinoma, a type of pancreatic cancer that often starts in the ducts of the pancreas. This study includes two phases Phase 2 involves dose escalation and optimization of telisotuzumab adizutecan with FOLFOX, followed by Phase 3 where participants receive the optimal dose or standard care treatment. Approximately 900 participants will take part over about six years. Participants in Phase 2 receive intravenous telisotuzumab adizutecan with FOLFOX at increasing doses, then are randomized to receive one of two optimized doses with FOLFOX or standard care fluorouracil, leucovorin, oxaliplatin, and irinotecan. In Phase 3, participants are randomized to receive the optimal dose of telisotuzumab adizutecan with FOLFOX or standard care. The treatment duration in each phase is approximately two years, with administration through IV infusions. During the study, participants attend regular visits at approved hospitals or clinics for medical assessments including blood tests and questionnaires to monitor side effects and treatment effects. The main outcomes measured include overall response and overall survival, along with progression-free survival, duration of response, clinical benefit, and quality of life assessments. The study monitors participants for about six years to evaluate these outcomes and safety.
CONDITIONS
Brief Title
A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma
Research Team
A
ABBVIE CALL CENTER
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here